Aquestive Therapeutics Inc (AQST)

[DorseyE]

Just added 1.5k to my portfolio.....

[DorseyE]

Missed earnings I wonder how we gonna hold up?

[DorseyE]

I was bracing for a pull back, glad I was wrong!

[midastouch017]

Nice uptick today too!

[DorseyE]

Will AQST Report Negative Earning Next Week?
Zack’s Equity
Aquestive Therapeutics (AQST) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2020. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 5. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus Estimate

This specialty pharmaceutical company is expected to post quarterly loss of $0.52 per share in its upcoming report, which represents a year-over-year change of +11.9%.

Revenues are expected to be $10.90 milli.
Estimate Revisions Trend

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
For Aquestive Therapeutics, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination makes it difficult to conclusively predict that Aquestive Therapeutics will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
influence on the upcoming number.

For the last reported quarter, it was expected that Aquestive Therapeutics would post a loss of $0.45 per share when it actually produced a loss of $0.48, delivering a surprise of -6.67%.

Over the last four quarters, the company has beaten consensus EPS estimates just once.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Aquestive Therapeutics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release

[DorseyE]

Funny, my accountant friend sent me the same caution.... love you brother-thanks

I definitely gotta remember that witH NBRV I’m heavily overloaded with that stock!

[midastouch017]

May it continue my friend, but remember the balance greed/fear! Take some off the table.
GLTY

[DorseyE]

Amen brother the biggest gainer in my portfolio today was AQST!

The 2nd was you know RDHL!

In fact all my stocks are up today!!!

[midastouch017]

Projections for the week anyone?

Up up and away!

[DorseyE]

Projections for the week anyone?

[DorseyE]

Aquestive Therapeutics Inc. (AQST) 
Next up is biotech Aquestive Therapeutics, which uses innovative drug delivery technology to redesign important medicines. With not one but two upcoming PDUFA dates, it’s not surprising that members of the Street think its $3.55 share price represents the ideal entry point. 
Weighing in for H.C. Wainwright, five-star analyst Raghuram Selvaraju believes that the most valuable piece of the puzzle is its anti-seizure candidate, Libervant, the PDUFA date for which is slated for September 27. “We estimate that Libervant could generate U.S. sales approaching $300 million by 2030. Libervant has been accorded Orphan Drug status, which would confer seven-year market exclusivity upon the product if approved,” he explained. 

Regarding Libervant’s launch, Selvaraju argues the fact that Sympazan (clobazam), an oral film for Lennox-Gastaut syndrome (LGS)-associated seizures, was launched prior to Libervant provides Aquestive with the opportunity to set up its commercial infrastructure.
It should also be noted that Selvaraju sees the recent share price weakness as not fully reflecting AQST’s value, with it boasting several other promising candidates in its pipeline. “In our view, the recent coronavirus crisis-driven market disruption has resulted in massively overdone attrition in Aquestive's share price. The company currently trades at a sub-$60 million market cap, which we believe does not reflect even the value of its manufacturing and licensing-related revenue, let alone revenue generated from its proprietary products,” he commented. 

One of these candidates is APL-130277, which could be approved on May 21. On top of this, AQST-108 could enter clinical testing this year, and with the annual U.S. epinephrine product market potentially totaling $5.2 billion by 2026, according to Coherent Market Insights, Selvaraju highlights the large opportunity for the biotech.

As a result, Selvaraju reiterated a Buy rating and $13 price target. Should this target be met, a twelve-month gain of 266% could be in the cards. (To watch Selvaraju’s track record, click here)

[DorseyE]

ADHD NDA Filing NDA submission announced March 2, 2020.
Exservan (riluzole) Oral Film Amyotrophic Lateral Sclerosis Approved FDA Approval announced November 22, 2019.
Sympazan Lennox-Gastaut Syndrome Approved Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Libervant - AQST-203 Epileptic seizures PDUFA PDUFA date September 27, 2020.
AQST-119 Erectile dysfunction CRL CRL issued November 16, 2018.
APL-130277 Parkinson’s Disease with motor fluctuations PDUFA CRL issued January 30, 2019 through partner Sunovion (private company). NDA refiled. New PDUFA date May 21, 2020.
AQST-108 Anaphylaxis Phase 1 Pivotal pharmacokinetic (PK) trials to be initiated before the end of 2020

Simplified version, click on link...
https://www.biopharmcatalyst.com/company/AQST
Be sure to CLICK ON DRUG INFORMATION

[DorseyE]

Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research
ZacksApril 15, 2020, 8:50 AM EDT
One stock that might be an intriguing choice for investors right now is Aquestive Therapeutics, Inc. AQST. This is because this security in the Medical – Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
https://finance.yahoo.com/news/aquestive-therapeutics-aqst-strong-industry-125012129.html

[DorseyE]

Bought more shares today@3.72!
Ready for PDUFA 5/21/2020..... LET’s GO!!!!

[DorseyE]

i love this one guys keep an EYE on them!!!!

[DorseyE]

Aquestive Therapeutics' (AQST, $3.52) patented PharmFilm technology offers an effective drug delivery method that can be customized to meet the specific absorption, bioavailability and onset of action requirements. And following the company's preliminary fourth-quarter earnings release, in which it provided its first-time 2020 outlook, analysts remain with two feet on board.

Writing for RBC Capital, Randall Stanicky notes that while the guidance came in lower than he expected, he believes management is being conservative. Specifically, he points out that the company excluded contributions from Libervant, which will most likely go up for approval in late September, and said Parkinson's Disease treatment APL-130277 will only contribute a Q4 milestone payment.

Based on this development, Stanicky writes, "Our new estimates reflect these revisions though we see potential for numbers to move higher pending further visibility on Libervant launch timing and expectations."

"Overall, while our numbers have been revised modestly lower, our fundamental view of the story is unchanged; 2020 is set to be an inflection year with several updates that can drive the stock higher including anticipated approval of key value driver Libervant," continues Stanicky, who has an Outperform rating and $9 price target on AQST shares.

Stanicky's price target is the most conservative among analysts who have sounded off on this low-priced stock during the past three months. Three other Buy calls have included $10, $13 and even $36 targets, averaging out to a consensus PT of $17, or more than 380% upside over the next 52 weeks. Investors interested in learning more can see AQST analysis on TipRanks.

[DorseyE]

LOST ON THAT ONE... RMTI
ON TO AQST PDUFA DATES 5/21/2020 & 9/27/2020
Check out this potential, REMEMBER CLICK ON DRUG INFORMATION
https://www.biopharmcatalyst.com/company/AQST

[DorseyE]

Aquestive Therapeutics



Market value: $116.5 million

TipRanks consensus price target: $17.00 (383% upside potential)

TipRanks consensus rating: Strong Buy

Aquestive Therapeutics' (AQST, $3.52) patented PharmFilm technology offers an effective drug delivery method that can be customized to meet the specific absorption, bioavailability and onset of action requirements. And following the company's preliminary fourth-quarter earnings release, in which it provided its first-time 2020 outlook, analysts remain with two feet on board.

Writing for RBC Capital, Randall Stanicky notes that while the guidance came in lower than he expected, he believes management is being conservative. Specifically, he points out that the company excluded contributions from Libervant, which will most likely go up for approval in late September, and said Parkinson's Disease treatment APL-130277 will only contribute a Q4 milestone payment.

Based on this development, Stanicky writes, "Our new estimates reflect these revisions though we see potential for numbers to move higher pending further visibility on Libervant launch timing and expectations."

"Overall, while our numbers have been revised modestly lower, our fundamental view of the story is unchanged; 2020 is set to be an inflection year with several updates that can drive the stock higher including anticipated approval of key value driver Libervant," continues Stanicky, who has an Outperform rating and $9 price target on AQST shares.

Stanicky's price target is the most conservative among analysts who have sounded off on this low-priced stock during the past three months. Three other Buy calls have included $10, $13 and even $36 targets, averaging out to a consensus PT of $17, or more than 380% upside over the next 52 weeks.

[DorseyE]

This site let me see the potential, so I’m interested!!!
Click on DRUG INFORMATION to see what i saw!!
https://www.biopharmcatalyst.com/company/AQST

[DorseyE]

1st time noticing this stock, potential looking GREAT, any thoughts on financials?

[JC$]

Wedbush has a $35 PT but, looks like they sold 30k shares in Jan ???

2020-01-16 13F Wedbush Securities Inc 98,489 62,434 -36.61 313 363 15.97
https://fintel.io/sos/us/aqst

[JC$]

Another note, if they come out with any news in the next couple weeks, it is a scam to sell their 25 million shares.

As of March 11, 2020, we have not sold any shares of our common stock under the Equity Distribution Agreement, which leaves all $25.0 million of common stock available under the Equity Distribution Agreement.
http://www.conferencecalltranscripts.org/PROS/summary2/?id=7584285

I wonder how many shares were sold as of March 12th and 13th ?

[JC$]

They said they have cash through 2020 , then why the 25 million share sale filing ?
Does not add up and also note to management ... not the right time to file something like that. Just my 2 cents. Feel like i can say this after losing thousands.
Thanks!

PS: its not the Corona virus's fault.

[JC$]

Feel like they might drop this to $1.. just my opinion.

[ClayTrader]

* * $AQST Video Chart 02-10-2020 * *

Link to Video - click here to watch the technical chart video

[TRAPPER JIM]

AQST WEEERE MOVING.

[JC$]

So this is how the market steals shares... I have know idea who would sell shares under $4 but, whatever.. I am assuming it is manipulation.

[ClayTrader]

* * $AQST Video Chart 02-06-2020 * *

Link to Video - click here to watch the technical chart video

[TRAPPER JIM]

Loaded up my boat. Bring on the BOUNCE

[TRAPPER JIM]

AQST bounce coming up

[doc7]

I think it's a big over reaction I am holding might buy more. Definite need for the drud-- and

orphan status entitles it to government subsidies.

[TRAPPER JIM]

$5.00 + COMING UP

[JC$]

Nevermind . I think I found it.

'Days to cover' is calculated by taking the number of currently shorted shares and dividing that amount by the average daily trading volume for the company in question. For example, if investors have shorted 2 million shares of ABC and it's average daily volume is 1 million shares then the days to cover is 2 days

AQST average volume is around 910k and looks like 315k shares shorted this morning. Guss they have to cover those today.

https://finviz.com/quote.ashx?t=aqst
https://iborrowdesk.com/report/AQST

[JC$]

Does anyone know how many days they have to cover the shares sold short this morning ? 2-3 ? TIA

[ClayTrader]

* * $AQST Video Chart 01-07-2020 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $AQST Video Chart 12-13-2019 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $AQST Video Chart 12-11-19 * *

Link to Video - click here to watch the technical chart video

[doc7]

the ride is not over i am still adding when i can regardless of price, we'll look back at this.

[ClayTrader]

* * $AQST Video Chart 11-25-2019 * *

Link to Video - click here to watch the technical chart video

[randomInvestor38]

every new low is higher then the last low, looking good, uptrend forming strong

[sanderburwil]

$AQST- FDA Approved early!!!
Aquestive Therapeutics -FDA approval for Exservan, its riluzole oral film for patients with ALS.

Expect a run come Monday morning folks. Wedbush price target $34
This was suddenly and so unexpected to be approved Friday evening. Pdufa was 30th

[sanderburwil]

$AQST- FDA Approved early!!!
Aquestive Therapeutics -FDA approval for Exservan, its riluzole oral film for patients with ALS.

Expect a run come Monday morning folks. Wedbush price target $34
This was suddenly and so unexpected to be approved Friday evening. Pdufa was 30th

[doc7]

Boom don't know how high

[ClayTrader]

* * $AQST Video Chart 11-11-19 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $AQST Video Chart 11-06-19 * *

Link to Video - click here to watch the technical chart video

[ADVFN_bioking]

BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM

[ClayTrader]

* * $AQST Video Chart 10-28-2019 * *

Link to Video - click here to watch the technical chart video

[ADVFN_bioking]

looks like big news coming

[ADVFN_bioking]

BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM

[ADVFN_bioking]

RALLYYYYYYYYYYYYYYYYYy